£35.0M
The Series A round was led by Syncona and included a £1m investment from the UCL Technology Fund.
QT
Quell Therapeutics
Developing engineered regulatory T cell therapies for immune dysfunction.
London, UK—Founded 2019
£35.0MTotal raised
Quell Therapeutics develops engineered regulatory T cell therapies to treat conditions involving immune dysfunction.
Categories
Team
IM
Iain McGill
CEO
HS
Hans Stauss
Professor
EM
Emma Morris
Professor